The present invention relates to N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenylsulfonamide compounds which are useful as inhibitors of protein kinases, more specifically BRAF or mutant forms thereof, to pharmaceutical composition comprising such compounds, and to uses of such compounds in the treatment or prevention of diseases associated with deregulated protein kinase activity, such as cancer.